AI OOS investigation — Phase I and II, drafted from the evidence.
V5 opens the OOS from the LIMS result, walks Phase I (analyst, instrument, method, calculation) and Phase II (hypothesis, re-test) with AI-drafted assessments cited to the source records — and preserves every step of the reasoning for the auditor.
What breaks without this.
OOS investigations are inconsistent across analysts
Different investigators cover different ground; the checklist is a Word doc.
Phase I evidence is scattered
Instrument calibration, analyst training, method file, calculation worksheet — all live in different systems.
The auditor asks why re-tests were authorised
Written rationale for re-testing is either boilerplate or missing.
Records-by-execution. Compliance, by design.
OOS opens with the evidence pre-attached
Instrument last-calibration, analyst current training, method version, calculation trace and prior results for the same product — all linked at open.
Guided Phase I / Phase II
V5 enforces the FDA 2006 OOS investigation structure — no free-form skipping.
AI drafts each assessment
Analyst-error, instrument-error, method-error, product-quality-error assessments drafted from the pre-attached evidence.
Re-test rationale is a first-class record
Written hypothesis, sample plan and pre-approval — not an email chain.
Stability OOT included
Same lifecycle covers stability OOT with the trend context inline.
What to look for when you're buying.
OOS software succeeds when Phase I / II is enforced and re-test rationale is pre-approved. Criteria that separate compliant from checkbox.
FDA 2006 structure enforced
What it tests: Does the tool enforce Phase I and Phase II, or free-form?
Why it matters: Free-form is why 483s happen here.
V5: Enforced.
Evidence pre-attached
What it tests: Are instrument calibration, analyst training, method version pre-linked at open?
Why it matters: Digging for these mid-investigation loses time.
V5: Pre-attached.
Draft assessments per category
What it tests: Are analyst / instrument / method / product-quality assessments drafted?
Why it matters: Blank template invites boilerplate.
V5: Drafted from evidence.
Re-test rationale pre-approved
What it tests: Is written hypothesis and sample plan approved before analysis?
Why it matters: Retrospective rationale is a finding.
V5: Pre-approved with e-signature.
Stability OOT integrated
What it tests: Same lifecycle for stability OOT?
Why it matters: Two tools create two habits.
V5: One lifecycle.
Auditor export
What it tests: One-click signed investigation package?
Why it matters: Reg readiness on demand.
V5: One-click signed export.
Spreadsheet vs legacy QMS vs V5.
AI OOS vs paper Phase I/II and vs a legacy LIMS OOS module.
| Capability | Spreadsheet | Legacy QMS | V5 Ultimate |
|---|---|---|---|
| Phase I / II enforced | SOP only | Sometimes | Enforced |
| Evidence pre-attached | None | Rare | Native |
| Draft assessments | N/A | N/A | AI-drafted with citations |
| Re-test pre-approval | Sometimes | E-signed record | |
| Stability OOT | Separate | Separate module | Same lifecycle |
The clauses, verbatim — and how V5 answers each.
The OOS clauses inspectors know cold.
Investigation should be conducted in a timely, thorough, unbiased, well-documented, and scientifically sound manner.
V5: Structure is enforced; timeliness is measured; documentation is native.
Any unexplained discrepancy... whether or not the batch has already been distributed, shall be thoroughly investigated.
V5: Post-distribution triggers are supported; re-open with full audit trail.
Interpretation and treatment of analytical data.
V5: Statistical treatment tools included; treatment is documented, not implicit.
Evaluation of stability data.
V5: Stability OOT evaluation follows ICH Q1E; adjacent-point analysis included.
Step by step on the floor.
OOS lifecycle goes live once LIMS results feed V5.
- 1Setup
LIMS wired
LIMS result stream feeds OOS trigger.
- 2Phase I
Analyst / instrument / method / calc
Guided Phase I with drafted assessments.
- 3Decision
Assignable cause found or Phase II authorised
Written re-test hypothesis pre-approved.
- 4Phase II
Product-quality investigation
Batch, process and material investigation completed.
- 5Closure
Disposition and CAPA
Batch disposition and CAPA (if warranted) close the OOS.
The math, with the assumptions visible.
OOS ROI shows in investigation duration and finding rate.
Median OOS duration
Evidence pre-attached; drafting parallelised.
483 rate on OOS clauses
Enforced structure removes the finding class.
Reviewer effort
Draft + evidence collapses the review burden.
OOS-driven 483s are the fastest to close on V5; the ROI is usually a full inspection cycle.
What changed on the floor.
Setting
A US generics site with a repeat 483 citing inadequate OOS investigations.
Before
OOS investigations averaged 68 days; the 483 recurred at the next inspection.
After
Twelve months post-cutover, median 32 days; no OOS-clause 483 at the following inspection.
Proof points
- Consistent Phase I / Phase II across analysts and sites
- Every assessment cites the source record
- Re-test rationale is pre-approved, not backfilled
- Stability OOT and release OOS share the workflow
Built to satisfy
- FDA Guidance for Industry: Investigating OOS Test Results (2006)
- 21 CFR 211.192 (production record review)
- USP <1010> (analytical data — interpretation and treatment)
- ICH Q1E (evaluation of stability data)
- EU GMP Chapter 6 §6.34 (out-of-specification)
Related on V5
Frequently asked questions
Is this a replacement for our LIMS?+
No — V5 works with your existing LIMS or with V5 LIMS. The OOS lifecycle sits above the result.
How does re-test authorisation work?+
Written hypothesis and sampling plan are e-signed before analysis; the retrospective 'we retested because…' pattern is structurally blocked.
What about stability shelf-life adjustments?+
Stability OOT with adjacent-point analysis and ICH Q1E-consistent evaluation is built into the same flow.
See V5 on your own line.
Free trial, no card. Live in 7 days with guided onboarding.